Memphasys Posts Record Revenue and Largest Felix™ Deal with Monash IVF

Record Revenue and Major Contract with Monash IVF

Memphasys Limited (ASX:MEM) capped FY26 with its most commercially active quarter yet, reporting a record $150,000 in revenue for Q4, a 34% increase on the March quarter. This pushed full year revenue to $273,000, with 96% generated in the second half. The standout development was the execution of a 12-month exclusive national supply agreement with Monash IVF Group, Australia’s largest Felix™ commercial partner to date, covering 22 clinics. The deal follows a successful multi-site clinical trial and sets the stage for a full rollout after an initial three-month pilot phase.

Accelerated Expansion into UK and Southeast Asia

Memphasys accelerated its UK market entry, with four IVF groups actively trialling Felix™ and placing initial orders shortly after the Company’s MHRA approval. This rapid uptake in one of the world's largest fertility markets signals growing international traction. Meanwhile, the Company made its first moves into Southeast Asia, signing exclusive distribution agreements in Vietnam and, post-quarter, Thailand. Combined, these Southeast Asian contracts represent approximately $961,000 in minimum contracted sales, supporting the Company’s strategy to diversify its global footprint.

Strengthening Recurring Revenue in MENA and Regulatory Milestones

In the Middle East and North Africa (MENA) region, Memphasys’ commercial partner ITL placed a further 1,000-cartridge order, doubling the throughput capacity at Qatar’s Hamad Medical Corporation and bringing total orders to 1,800 cartridges within two quarters. Regulatory approvals are pending in key markets: Turkey’s registration is expected imminently, with orders anticipated in the September quarter; India’s CDSCO approval is also expected soon, activating a $98,820 minimum contract with Andrology Center Coimbatore; and Vietnam’s regulatory nod is forecast for August, enabling commercial launch with TMSC Vietnam.

Operational Efficiency and Financial Position

Memphasys demonstrated sharp cost discipline, slashing quarterly operating cash outflows by 71% since December 2025, down to $422,000 in Q4. This improvement follows the completion of one-off restructuring costs and reflects tighter control over administration and staff expenses, even as marketing spend increased to support international conferences such as ESHRE in London. The Company completed a $1.2 million placement in June to fund manufacturing and inventory build, boosting cash on hand to $1.179 million, enough to cover nearly three quarters of operating costs at current burn rates.

Board Renewal and Strategic Leadership

On the governance front, Memphasys appointed David Tasker as Non-Executive Chairman in May 2026, bringing two decades of investor relations and ASX small-cap strategy experience. Tasker’s longstanding advisory role and shareholder history with Memphasys adds continuity as the Company scales its commercial operations globally.

Commercial Agreements Now Exceed $3 Million

The Company’s contracted sales for FY26 have surpassed $3 million, exceeding its $2 million target, with agreements now spanning Australia, Europe, the UK, MENA, India, Japan, Vietnam, and Thailand. The recent three-year exclusive deal with IVF Envimed in Thailand, valued at approximately $430,500, was signed post-quarter and is expected to commence revenue recognition after Thai FDA approval later this year. This broadening footprint and growing base of recurring cartridge sales underpin Memphasys’ ambition to establish Felix™ as a global standard in sperm preparation for assisted reproductive technologies.